Amendment: SEC Form SCHEDULE 13D/A filed by Anebulo Pharmaceuticals Inc.

Item 6 is hereby amended and supplemented by adding the following: As previously disclosed, on December 22, 2024, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the "Company"), entered into a securities purchase agreement (the "Purchase Agreement") with 22NW Fund, LP ("22NW"), as well as other institutional accredited investors (the "Investors"), pursuant to which the Company issued to the Investors, in a private placement priced at-the-market (the "Private Placement"), an aggregate of 15,151,514 shares of Common Stock, of which 10,101,010 of such shares (the "Shares") were issued to 22NW, a greater than 5% stockholder of the Company that is controlled by Aron English, a director of the Company. The Private Placement closed on December 23, 2024. On February 24, 2025, the Company entered into a lock-up agreement (the "Lock-Up Agreement") with 22NW pursuant to which 22NW agreed not to vote, sell, transfer, pledge or otherwise dispose of the Shares that were issued to it in the Private Placement. Pursuant to the Lock-Up Agreement, the Company agreed to hold a stockholder meeting no later than April 30, 2025 (the "2025 Annual Meeting") and to submit a proposal for the removal of the voting and transfer restrictions set forth in the Lock-Up Agreement (the "Proposal") at the 2025 Annual Meeting. The Lock-Up Agreement further provides that any failure of the Company to hold a stockholder meeting to remove the lock-up restrictions by April 30, 2025 or to have the restrictions on voting and transfer of the Shares removed after receiving stockholder approval of the Proposal would be deemed a breach of the Lock-Up Agreement and 22NW would have a right to have the Shares redeemed. In conjunction with entering into the Lock-Up Agreement, the Company executed an irrevocable letter (the "Irrevocable Instruction Letter"), which was acknowledged and agreed to by 22NW, instructing the Company's transfer agent not to allow the voting or sale, transfer, pledge or other disposition of the Shares until the Company's stockholders approve the removal of the lock-up restrictions at a stockholder meeting held for such purpose. The transfer agent has also been instructed to place a legend on the Shares noting that they are subject to the terms of the Lock-Up Agreement. On February 24, 2025 the Reporting Persons and Dr. Joseph Lawler entered into a support agreement (the "22NW Support Agreement"). Pursuant to the 22NW Support Agreement, the Reporting Persons have agreed that from and after the 2025 Annual Meeting and at every meeting of the holders of the Company's common stock thereafter that holders of common stock are requested to vote upon a proposal to elect Dr. Lawler to the board of directors of the Company, however called, and at every adjournment or postponement thereof, the Reporting Persons shall vote the shares they beneficially own and have in their control at the time of such meeting in favor of the election of Dr. Lawler. On February 24, 2025 the Reporting Persons and Dr. Joseph Lawler entered into a second support agreement (the "Lawler Support Agreement"). Pursuant to the Lawler Support Agreement, Dr. Lawler has agreed to vote all of the common stock of the Company owned or controlled by him at the 2025 Annual Meeting in favour of the Proposal (or at any other stockholder meeting held to vote on the Proposal). Also pursuant to the Lawler Support Agreement, Dr. Lawler has agreed that from and after the 2025 Annual Meeting and at every meeting of the holders of the Company's common stock thereafter that holders of common stock are requested to vote upon a proposal to elect Mr. Aron English to the board of directors of the Company, however called, and at every adjournment or postponement thereof, Dr. Lawler shall vote the shares he beneficially owns and has in his control at the time of such meeting in favor of the election of Mr. English. Except as otherwise set forth in Amendment No. 2 to this Schedule 13D, there are no contracts, arrangements, understandings or similar relationships existing with respect to the securities of the Company between the Reporting Persons and any other person or entity.

Item 7 is hereby amended and supplemented by adding the following: Exhibit 2: Support Agreement dated February 24, 2025 among 22NW Fund, LP, Pharma Investors, LLC and Dr. Joseph Lawler